• Mashup Score: 0
    Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Bertrand Tombal presents de-escalation strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC) Biographies: Bertrand Tombal, MD, PhD, Chairman of the Department of Surgery and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc,…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Treatment de-escalation strategies in #mHSPC. #APCCC22 presentation by @BertrandTOMBAL @UCLouvain_be. #WatchNow on UroToday > https://t.co/7cRKtepsyA @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/AYK9i1rOEa

  • Mashup Score: 1
    Are There Predictors for Successful Treatment of Oligometastatic Prostate Cancer? APCCC 2022 Presentation - Piet Ost - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Piet Ost presents predictors for the successful treatment of patients with oligometastatic and oligoprogressive prostate cancer, Biographies: Piet Ost, MD, PhD, associate professor at Ghent University, Ghent, Belgium, and radiation oncologist at the Iridium Network, Antwerp, Belgium Related Content: APCCC 2022: Are There…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Are there predictors for successful treatment of oligometastatic #ProstateCancer? #APCCC22 presentation by @piet_ost @uzgent. #WatchNow on UroToday > https://t.co/10XdBWSKpy @APCCC_Lugano https://t.co/AY9UjHmxEW

  • Mashup Score: 0
    Are We Ready to Change Management Based on Next-Generation Imaging? YES: APCCC 2022 Presentation - Jason Efstathiou - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference, Jason Efstathiou presents why we are ready to change management based on next-generation imaging. Biographies: Jason Efstathiou, MD, Radiation Oncologist Professor of Radiation Oncology, Harvard Medical School, Vice-Chair, Faculty & Academic Affairs, and Director, Genitourinary Service, Department of Radiation Oncology, Clinical…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Are we ready to change management based on next-generation imaging? YES. #APCCC22 presentation by Jason Efstathiou, MD @harvardmed. #WatchNow on UroToday > https://t.co/LBxJYcwLGt @APCCC_Lugano @Silke_Gillessen @AOmlin @NehaVapiwala @MGHMedicine https://t.co/W1WqMwwCg6

  • Mashup Score: 3
    Who Needs Systemic Treatment With Salvage Radiotherapy? APCCC 2022 Presentation - Brandon Mahal - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Brandon Mahal presents on who needs systemic treatment with salvage radiotherapy. Biographies: Brandon Mahal, MD, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL Related Content: APCCC 2022: Who Needs Systemic Treatment With Salvage RT? Read the Full Video Transcript…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Who needs systemic treatment with salvage radiotherapy? #APCCC22 presentation @BrandonMahal @SylvesterCancer #WatchNow on UroToday > https://t.co/1eNfSoldMy @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/QfmpbRwQGc

  • Mashup Score: 0
    Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA….

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Advantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @morr316 @MSKCancerCenter. #WatchNow on UroToday > https://t.co/MRrDZvYFTf @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/pmciyCt6UI

  • Mashup Score: 0
    Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore - 1 year(s) ago

    Neal Shore joins Alicia Morgans during APCCC 2022 to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). Drs. Shore and Morgans consider the many treatment options now available as Dr. Shore emphasizes that monotherapy should no longer be an option. Finally, important concerns about bone health and its impact on…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Lutetium-617 - treatment sequencing considerations for #mCRPC. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber to discuss sequencing strategies to implement lutetium-617. #WatchNow > https://t.co/gbal3zYrOA #APCCC22 https://t.co/jim7ZVDpzn

  • Mashup Score: 0
    Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Caroline Clarke presents on health economics in metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Caroline S. Clarke, PhD, MSci, BA (Hons), Senior Research Associate in Health Economics, University College London, London, UK Related Content: APCCC 2022: Optimal Treatment for mHSPC from a Health…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Optimal treatment for #mHSPC from a health economics standpoint. #APCCC22 presentation by @cazline42 @ucl. #WatchNow on UroToday > https://t.co/z9QqjfOiK3 @APCCC_Lugano @silkegillessen @AOmlin https://t.co/obnfooSsBs

  • Mashup Score: 0
    Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans - 1 year(s) ago

    At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alicia Morgans presents the treatment of vulnerable/frail patients with metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content:…

    Source: UroToday
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Treatment of vulnerable/frail patients with #mHSPC. #APCCC22 presentation by @CaPsurvivorship @DanaFarber. #WatchNow on UroToday > https://t.co/GvGS59RzQL @APCCC_Lugano @silkegillessen @AOmlin https://t.co/SQQuxqGVG3

Load More